EMA Decision Due For Minoryx’s Leriglitazone & Apellis’ Pegcetacoplan

The European Medicines Agency is this week due to decide whether to back pan-EU marketing authorization for five new medicines, including a combination antibiotic product and a drug for chemotherapy-induced neutropenia.

Conference room interior with big table and screen — The EMA's Human medicines committee will meet this week to decide which drugs should be approved in the EU • Source: Shutterstock

Minoryx Therapeutics could soon learn whether its orphan drug leriglitazone has been recommended for EU marketing approval by the European Medicines Agency to treat adult male patients with X-linked adrenoleukodystrophy.

Leriglitazone, a novel blood-brain barrier-penetrant PPARγ agonist, is one of five new products for which initial EU marketing authorization applications (MAAs) are listed as being up for an opinion on the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

EMA Decision Due For Minoryx’s Leriglitazone & Apellis’ Pegcetacoplan

Read the full article – start your free trial today!

More from Approvals

More from Product Reviews